UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

US healthcare costs attributable to type A and type B influenza

Human vaccines & immunotherapeutics, 2017-09, Vol.13 (9), p.2041-2047

2017

Volltextzugriff (PDF)

The Effects of Infliximab Therapy on Health-Related Quality of Life in Ulcerative Colitis Patients

The American journal of gastroenterology, 2007-04, Vol.102 (4), p.794-802

2007

Volltextzugriff (PDF)

Analysis of real-world health care costs among immunocompetent patients aged 50 years or older with herpes zoster in the United States

Human vaccines & immunotherapeutics, 2017-08, Vol.13 (8), p.1861-1872

2017

Volltextzugriff (PDF)

Is patient insurance type related to physician recommendation, administration and referral for adult vaccination? A survey of US physicians

Human vaccines & immunotherapeutics, 2019-09, Vol.15 (9), p.2217-2226

2019

Volltextzugriff (PDF)

Impact of the change of copay policy in Medicare Part D on zoster vaccine uptake among Medicare beneficiaries in a managed care organization

BMC health services research, 2017-07, Vol.17 (1), p.503-503, Article 503

2017

Volltextzugriff (PDF)

Unemployment and disability in patients with moderately to severely active Crohn's disease

Journal of clinical gastroenterology, 2005-05, Vol.39 (5), p.390-395

2005

Volltextzugriff (PDF)

The effects of infliximab maintenance therapy on health-related quality of life

The American journal of gastroenterology, 2003-10, Vol.98 (10), p.2232-2238

2003

Volltextzugriff (PDF)

Effect of infliximab therapy on employment, time lost from work, and productivity in patients with psoriatic arthritis

Journal of rheumatology, 2006-11, Vol.33 (11), p.2254

2006

Volltextzugriff (PDF)

Assessing bleeding rates, related clinical impact and factor utilization in German hemophilia B patients treated with extended half-life rIX-FP compared to prior drug therapy

Current medical research and opinion, 2020-01, Vol.36 (1), p.9-15

2020

Volltextzugriff (PDF)

Assessing prophylactic use and clinical outcomes in hemophilia A patients treated with rVIII‐SingleChain and other common rFVIII products in Germany

European journal of haematology, 2020-04, Vol.104 (4), p.310-317

2020

Volltextzugriff (PDF)

Impact of Irritable Bowel Syndrome on Quality of Life and Resource Use in the United States and United Kingdom

Digestion, 1999-01, Vol.60 (1), p.77-81

1999

Volltextzugriff (PDF)

Assessing health care resource use, outcomes, and costs among Medicaid beneficiaries receiving factor IX prophylaxis for hemophilia B

Journal of managed care & specialty pharmacy, 2024-10, Vol.30 (10), p.1095-1105

2024

Volltextzugriff (PDF)

Assessing health plan payer’s budget impact of etranacogene dezaparvovec for the treatment of hemophilia B in the United States

Journal of managed care & specialty pharmacy, 2024-08, Vol.30 (8), p.805-816

2024

Volltextzugriff (PDF)

Structured Literature Review of the Economic and Humanistic Burden in Kidney Allograft Loss: SA-PO811

Journal of the American Society of Nephrology, 2022-11, Vol.33 (11S), p.826-826

2022

Volltextzugriff (PDF)

Matching-Adjusted Indirect Comparison of Recombinant Factor IX Albumin Fusion Protein Versus Recombinant Factor IX Fc Fusion Protein for Weekly Prophylactic Treatment of Hemophilia B

Advances in therapy, 2024-02, Vol.41 (2), p.649-658

2024

Volltextzugriff (PDF)

Economic and humanistic burden in kidney transplant rejection: a literature review

Expert review of pharmacoeconomics & outcomes research, 2024-03, Vol.24 (3), p.343-352

2024

Volltextzugriff (PDF)

Analysis of pooled real-world data from Germany, Italy, and the United States of rVIII-SingleChain compared with standard- and long-acting FVIII products for prophylaxis of hemophilia A

Current medical research and opinion, 2022-07, Vol.38 (7), p.1133-1139

2022

Volltextzugriff (PDF)

Analysis of long-term clinical and cost impact of etranacogene dezaparvovec for the treatment of hemophilia B population in the United States

Journal of medical economics, 2024-05, Vol.27 (1), p.1-13

2024

Volltextzugriff (PDF)

Analysis of Vascular Event Risk After Herpes Zoster From 2007 to 2014 US Insurance Claims Data

Mayo Clinic proceedings, 2019-05, Vol.94 (5), p.763-775

2019

Volltextzugriff (PDF)

Indirect treatment comparisons of the gene therapy etranacogene dezaparvovec versus extended half‐life factor IX therapies for severe or moderately severe haemophilia B

Haemophilia : the official journal of the World Federation of Hemophilia, 2024-01, Vol.30 (1), p.75-86

2024

Volltextzugriff (PDF)

A Real-World Analysis of Commonly Prescribed FVIII Products Based on U.S. Medical Charts: Consumption and Bleeding Outcomes in Hemophilia A Patients

Journal of managed care & specialty pharmacy, 2020-10, Vol.26 (10), p.1258-1265

2020

Volltextzugriff (PDF)

Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn’s disease

Gastroenterology (New York, N.Y. 1943), 2005-04, Vol.128 (4), p.862-869

2005

Volltextzugriff (PDF)

Systematic review and analysis of efficacy of recombinant factor IX products for prophylactic treatment of hemophilia B in comparison with rIX-FP

Journal of medical economics, 2019-10, Vol.22 (10), p.1014-1021

2019

Volltextzugriff (PDF)

Comparing Factor Use and Bleed Rates in U.S. Hemophilia A Patients Receiving Prophylaxis with 3 Different Long-Acting Recombinant Factor VIII Products

Journal of managed care & specialty pharmacy, 2020-04, Vol.26 (4), p.504-512

2020

Volltextzugriff (PDF)

Risk of Transient Ischemic Attack and Stroke in Patients with Herpes Zoster: 2007–2014 US Claims Data Analysis (S15.008)

Neurology, 2018-04, Vol.90 (15_supplement)

2018

Volltextzugriff (PDF)

1 – 25 von 63

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(60)
Mit Volltextzugriff
(40)

Publikationsform

Artikel
(63)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(41)
Life Sciences & Biomedicine
(37)
Humans
(28)
Male
(21)
Adult
(17)
Female
(17)
Middle Aged
(14)
Health Care Sciences & Services
(11)
Quality Of Life
(11)
Treatment Outcome
(9)
Gastroenterology & Hepatology
(8)
General & Internal Medicine
(8)
Medicine, General & Internal
(8)
Pharmacology & Pharmacy
(8)
Retrospective Studies
(8)
Aged
(7)
Double-Blind Method
(7)
Infliximab
(7)
Adolescent
(6)
Antibodies, Monoclonal - Therapeutic Use
(6)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

US healthcare costs attributable to type A and type B influenza

The Effects of Infliximab Therapy on Health-Related Quality of Life in Ulcerative Colitis Patients

Analysis of real-world health care costs among immunocompetent patients aged 50 years or older with herpes zoster in the United States

Is patient insurance type related to physician recommendation, administration and referral for adult vaccination? A survey of US physicians

Impact of the change of copay policy in Medicare Part D on zoster vaccine uptake among Medicare beneficiaries in a managed care organization

Unemployment and disability in patients with moderately to severely active Crohn's disease

The effects of infliximab maintenance therapy on health-related quality of life

Effect of infliximab therapy on employment, time lost from work, and productivity in patients with psoriatic arthritis

Assessing bleeding rates, related clinical impact and factor utilization in German hemophilia B patients treated with extended half-life rIX-FP compared to prior drug therapy

Assessing prophylactic use and clinical outcomes in hemophilia A patients treated with rVIII‐SingleChain and other common rFVIII products in Germany

Impact of Irritable Bowel Syndrome on Quality of Life and Resource Use in the United States and United Kingdom

Assessing health care resource use, outcomes, and costs among Medicaid beneficiaries receiving factor IX prophylaxis for hemophilia B

Assessing health plan payer’s budget impact of etranacogene dezaparvovec for the treatment of hemophilia B in the United States

Structured Literature Review of the Economic and Humanistic Burden in Kidney Allograft Loss: SA-PO811

Matching-Adjusted Indirect Comparison of Recombinant Factor IX Albumin Fusion Protein Versus Recombinant Factor IX Fc Fusion Protein for Weekly Prophylactic Treatment of Hemophilia B

Economic and humanistic burden in kidney transplant rejection: a literature review

Analysis of pooled real-world data from Germany, Italy, and the United States of rVIII-SingleChain compared with standard- and long-acting FVIII products for prophylaxis of hemophilia A

Analysis of long-term clinical and cost impact of etranacogene dezaparvovec for the treatment of hemophilia B population in the United States

Analysis of Vascular Event Risk After Herpes Zoster From 2007 to 2014 US Insurance Claims Data

Indirect treatment comparisons of the gene therapy etranacogene dezaparvovec versus extended half‐life factor IX therapies for severe or moderately severe haemophilia B

A Real-World Analysis of Commonly Prescribed FVIII Products Based on U.S. Medical Charts: Consumption and Bleeding Outcomes in Hemophilia A Patients

Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn’s disease

Systematic review and analysis of efficacy of recombinant factor IX products for prophylactic treatment of hemophilia B in comparison with rIX-FP

Comparing Factor Use and Bleed Rates in U.S. Hemophilia A Patients Receiving Prophylaxis with 3 Different Long-Acting Recombinant Factor VIII Products

Risk of Transient Ischemic Attack and Stroke in Patients with Herpes Zoster: 2007–2014 US Claims Data Analysis (S15.008)

Suchergebnisse filtern